Leerink Partnrs Has Positive Outlook of Cencora Q2 Earnings

Cencora, Inc. (NYSE:COR) – Equities research analysts at Leerink Partnrs increased their Q2 2025 earnings estimates for Cencora in a research report issued to clients and investors on Thursday, January 2nd. Leerink Partnrs analyst M. Cherny now anticipates that the company will earn $4.23 per share for the quarter, up from their previous forecast of $4.12. The consensus estimate for Cencora’s current full-year earnings is $14.93 per share. Leerink Partnrs also issued estimates for Cencora’s Q3 2025 earnings at $3.87 EPS, Q4 2025 earnings at $3.84 EPS, FY2025 earnings at $15.39 EPS, FY2026 earnings at $17.11 EPS and FY2028 earnings at $20.75 EPS.

A number of other research analysts have also commented on COR. Wells Fargo & Company lowered their price objective on shares of Cencora from $249.00 to $237.00 and set an “equal weight” rating on the stock in a research note on Friday, December 13th. Barclays lifted their price target on Cencora from $263.00 to $290.00 and gave the company an “overweight” rating in a research report on Thursday, November 7th. StockNews.com lowered Cencora from a “strong-buy” rating to a “buy” rating in a report on Friday, September 20th. Evercore ISI lifted their target price on Cencora from $250.00 to $285.00 and gave the stock an “outperform” rating in a report on Thursday, November 7th. Finally, UBS Group upped their price target on shares of Cencora from $275.00 to $285.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to MarketBeat, Cencora presently has a consensus rating of “Moderate Buy” and an average price target of $275.60.

Cencora Stock Up 2.1 %

Cencora stock opened at $233.78 on Monday. The company’s 50-day moving average price is $237.38 and its two-hundred day moving average price is $233.51. The stock has a market cap of $45.18 billion, a price-to-earnings ratio of 31.13, a PEG ratio of 1.54 and a beta of 0.49. Cencora has a 52 week low of $208.58 and a 52 week high of $253.27. The company has a current ratio of 0.88, a quick ratio of 0.53 and a debt-to-equity ratio of 4.84.

Cencora Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, November 29th. Stockholders of record on Friday, November 15th were given a $0.55 dividend. This is an increase from Cencora’s previous quarterly dividend of $0.51. This represents a $2.20 annualized dividend and a dividend yield of 0.94%. The ex-dividend date of this dividend was Friday, November 15th. Cencora’s dividend payout ratio (DPR) is 29.29%.

Insider Activity

In other news, EVP Silvana Battaglia sold 1,678 shares of the company’s stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $228.72, for a total value of $383,792.16. Following the transaction, the executive vice president now owns 20,329 shares in the company, valued at $4,649,648.88. This represents a 7.62 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Chairman Steven H. Collis sold 21,509 shares of the firm’s stock in a transaction that occurred on Tuesday, November 19th. The stock was sold at an average price of $242.16, for a total transaction of $5,208,619.44. Following the sale, the chairman now owns 306,752 shares of the company’s stock, valued at approximately $74,283,064.32. This represents a 6.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 94,696 shares of company stock worth $22,862,734 over the last 90 days. 15.80% of the stock is owned by company insiders.

Institutional Investors Weigh In On Cencora

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Arizona State Retirement System boosted its position in Cencora by 6.3% during the second quarter. Arizona State Retirement System now owns 52,047 shares of the company’s stock valued at $11,726,000 after purchasing an additional 3,089 shares during the last quarter. Private Advisor Group LLC grew its stake in shares of Cencora by 11.5% in the 2nd quarter. Private Advisor Group LLC now owns 6,785 shares of the company’s stock valued at $1,529,000 after buying an additional 700 shares in the last quarter. Candriam S.C.A. grew its stake in shares of Cencora by 21.9% in the 2nd quarter. Candriam S.C.A. now owns 7,897 shares of the company’s stock valued at $1,779,000 after buying an additional 1,420 shares in the last quarter. Savant Capital LLC increased its holdings in Cencora by 2.1% in the second quarter. Savant Capital LLC now owns 6,511 shares of the company’s stock worth $1,467,000 after buying an additional 132 shares during the last quarter. Finally, SRS Capital Advisors Inc. lifted its stake in Cencora by 6.7% in the second quarter. SRS Capital Advisors Inc. now owns 3,338 shares of the company’s stock valued at $752,000 after acquiring an additional 210 shares during the last quarter. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.